Full Press Release Details
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022.
ALXO
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Key Takeaway: ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Price reaction · baseline $19.19 (2022-01-07 close) · clean, no other ALXO news in the window
day 0 close · peak
+2.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)